Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-AnalysisReportar como inadecuado




Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background

The prognostic value of epidermal growth factor receptor EGFR mutations in resected non-small cell lung cancer NSCLC remains controversial. We performed a systematic review with meta-analysis to assess its role.

Methods

Studies were identified via an electronic search on PubMed, Embase and Cochrane Library databases. Pooled hazard ratio HR for disease-free survival DFS and overall survival OS were calculated for meta-analysis.

Results

There were 16 evaluated studies n = 3337 in the meta-analysis. The combined HR evaluating EGFR mutations on disease free survival was 0.96 95% CI 0.79–1.16 P = 0.65. The combined HR evaluating EGFR mutations on overall survival was 0.86 95% CI 0.72–1.04 P = 0.12. The subgroup analysis based on univariate and multivariate analyses in DFS and OS showed no statistically significant difference. There was also no statistically significant difference in DFS and OS of stage I NSCLC patients.

Conclusion

The systematic review with meta-analysis showed that EGFR mutations were not a prognostic factor in patients with surgically resected non-small cell lung cancer. Well designed prospective study is needed to confirm the result.



Autor: Zhixuan Zhang, Ting Wang, Jun Zhang, Xiaohong Cai, Changchuan Pan, Yu Long, Jing Chen, Chengya Zhou, Xude Yin

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados